Recurrent Glioblastoma Clinical Trial - ReSPECT-GBM
The ReSPECT-GBM trial investigates the safety and efficacy of REYOBIQTM (rhenium Re186 obisbemeda) as a targeted radiolabeled therapy for recurrent glioblastoma.
Recurrent glioblastoma has limited treatment options and a poor prognosis, underscoring the need for novel therapeutic strategies.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma